Accordingly, IQS-01.01RS and CPI203 combinatorial treatment achieved a synergistic downregulation of MYC an improved tumor growth inhibition in DLBCL cell lines and xenograft model [67]. This evidence concerns the gene MYC and diffuse large B-cell lymphoma.